Course Programme & Exhibition Information





President: Prof. Olivier Lucidarme

Cancer Imaging: Current guidelines for best practice

22nd Annual Teaching Course

25-27 September 2023

The British Museum, Great Russell Street London, WC1E 7JW

icimagingsociety.org.uk

Contents

03 ICIS 2023 Faculty and Judging panels

05 Floor plan

Scientific programme: Monday 25 SeptemberScientific programme: Tuesday 26 September

10 Scientific programme: Wednesday 27 September

10 Scientific programme: Wednesday 27 September

11 Future meetings

12 Scientific paper sessions

13 Scientific poster exhibition

16 Exhibitors and sponsors

22 2023 Social events and sponsor symposia

23 News

Key to Scientific Programme

Keynote Lecture

BP Lecture Theatre (BP LT)

Stevenson Theatre

Computer Hands-on Workshop

Scientific Papers

Break

Important Information

Please ensure you complete the electronic feedback survey every evening, once all lectures have finished, to ensure receipt of your CPD certificate. Please check the inbox of your email used to register for this course (the one we have been emailing you on) to find the link to the survey each day.

Once all surveys have been completed for the days you have attended, a CPD certificate will be sent.

ICIS 2023 is accredited by:

icis 2025 is accredited by

Royal College of Radiologists – participants will receive 18.5 CPD credits in total for the three-day course, awarded according to the CPD scheme of the Royal College of Radiologists. Monday 7 credits, Tuesday 6.5 credits, Wednesday 5 credits.

The International Cancer Imaging Society 22nd Annual Teaching Course. 'Cancer Imaging: Current guidelines for best practice', London, United Kingdom, 25/09/2023-27/09/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

CPD certificates will be issued electronically, to the email address used to register for ICIS 2023. ICIS Members can download their CPD certificate in the Members' Area of the website, via their personal dashboard.

Faculty

ICIS Fellows

Arturo Chiti (Milan) Conor Collins (Dublin) Stefan Diederich (Düsseldorf) Mirko D'Onofrio (Verona) Khaled Elsaves (Houston) Fiona Fennessy (Boston) Luba Frank (Wauwatosa) Rosemarie Förstner (Salzburg) Jurgen Fütterer (Nijmegen) Bernhard Gebauer (Berlin) Richard Gore (Evanston) lav Heiken (Rochester) Ken Herrmann (Essen) Rodney Hicks (Melbourne) Michael Hofman (Melbourne) Thierry Huisman (Houston) Kartik Thaveri (Toronto) Pek-Lan Khong (Singapore) Ann King (Hong Kong) Dow-Mu Koh (Sutton) Katie Krajewski (Boston) Gigin Lin (Taipei) Olivier Lucidarme (Paris) Marius Mayerhoefer (NYC/Vienna)

Christina Messiou (London) Giovanni Morana (Treviso) Giovanni Morana (Turin) Stephanie Nougaret (Boston) Wim Oyen (Arnhem) Anwar Padhani (London) Valeria Panebianco (Rome) Nickolas Papanikolaou (Lisbon) Giuseppe Petralia (Milan) Thorsten Persigehl (Cologne) Fred Prior (Arkansas) Andrea Rockall (London) Evis Sala (Rome) Wolfgang Schima (Vienna) Atul Shinagare (Boston) Aslam Sohaib (London) Nicola Sverzellati (Parma) Bachir Taouli (New York) Alexander Towbin (Cincinatti) Annick D. Van den Abbeele (Boston) Alberto Vargas (New York) Sarah Vinnicombe (Cheltenham) Rozemariin Vliegenthart (Groningen) Stephan Voss (Boston) Mathilde Wagner (Paris)

Invited Faculty

Kunwar Bhatia (London) Sotirios Bisdas (London) Philippe Charlier (Paris) Laura Haefliger (Lausanne) Roberto lezzi (Rome) Sarah Montagne (Paris)

Beth McCarville (Memphis)

Theresa McLoud (Boston)

Sebastien Mule (Paris) Raphaele Renard Penna (Paris) Maxime Ronot (Paris) Gilles Russ (Paris) Marc Zins (Paris)

Programme Planning Committee

Thierry Huisman (Houston) Pek-Lan Khong (Singapore) Dow-Mu Koh (Sutton) Olivier Lucidarme (Paris) Wim Oyen (Arnhem) Wolfgang Schima (Vienna) Annick D. Van den Abbeele (Boston)


Scientific Committee and Judges

Conor Collins (Dublin) Fiona Fennessy (Boston) Christina Messiou (London) Stephanie Nougaret (Boston) Valeria Panebianco (Rome) Alberto Vargas (New York)

- **1** GE HealthCare
- 2 Guerbet
- **3** Siemens Healthineers
- 4 Olea
- 5 Mint Medical

- 6 Bracco
- 7 ICIS and BMC
- 8 Bayer
- 9 Hermes
- 10 Deeplink





Scientific Programme: Monday 25 September

○ TIME	♠ SUBJECT & SPEAKER	VENUE	
08:00 - 08:45	Registration		
08:45 - 09:00	Welcome: Cancer Imaging – guidelines recommendations and consensus statements		
09:00 - 10:40	How to do and report oncological imaging?	BP LT	
09:00 - 09:20	Consensus statements: how and why – K. Herrmann		
09:20 - 09:40	Disease-specific structured reports and report language – A.	Shinagare	
09:40 - 09:50	Scientific Presentation		
09:50 - 10:10	RECIST, modified criteria and their application in various oncological settings – A. Sohaib		
10:10 - 10:30	Beyond RECIST 1.1 – R. Gore		
10:40 - 11:00	Break		
11:00 - 12:40	- 12:40 Pancreatic Cancer: The sadly rising star BP LT		
11:00 – 11:20	20 Guidelines and structured report for pretreatment assessment – M. Wagner		
11:20 - 11:40	Expert consensus for post-treatment assessment and new paradigms – M. Zins		
11:40 - 11:50	Scientific Presentation		
11:50 - 12:10	Borderline resectable and locally advanced pancreatic cancer: role of FDG PET in assessing response to neoadjuvant therapy and predicting survival – . Heiken		
12:10 - 12:30	Pancreatic cystic lesions: can we make sense of the guidelines? – G. Morana (Treviso)		
11:00 - 12:40	Lung Cancer, Still There!	Stevenson	
11:00 - 11:20	Lung cancer screening – R. Vliegenthart		
11:20 - 11:40	Guidelines for lung nodule evaluation (Fleischner Society) – T. McLoud		
11:40 - 11:50	O Scientific Presentation		
11:50 - 12:10	Staging lung cancer – A. Chiti		
12:10 - 12:30	5 5		
11:00 – 12:00	Hands-On Workshop 1 – Head and Neck A. King / K.Bhatia Rooms A&B		
12:00 - 13:00	Hands-On Workshop 2 – MRI of the prostate: Selection of didactic cases R. Renard Penna/ S. Montagne	Rooms A&B	
12:40 - 13:30	Lunch & 30-minute Satellite Symposium		

○ TIME	ME	
13:30 - 14:00	Keynote Lecture 1: Radiology at the museum: mummies, skeletons, relics BP LT and statues – Philippe Charlier	
14:00 - 15:40	Thyroid/NET/Adrenal: Small glands with big effects	BP LT
14:00 - 14:20	Diagnostic imaging of thyroid nodules: find your pathway through the jungle of guidelines – G. Russ	
14:20 - 14:40	Adrenal tumours: diagnostic work-up – K. Elsayes	
14:40 - 14:50	Scientific Presentation	
14:50 - 15:10	:10 Clinical practice guidelines for the use of minimally invasive treatments in malignant thyroid lesions – G. Russ	
15:10 - 15:30	Imaging strategy of GEP-NET – W. Schima	
14:00 - 15:00	O – 15:00 Hands-On Workshop 3 – Lung-RADS A. Chiti / L. Frank	
15:40 - 16:00	00 Break	
16:00 - 17:40	7:40 Colorectal Cancer: Everyone concerned BP LT	
16:00 - 16:20	Pre-treatment Rectal cancer: Guidelines for imaging and reporting – K. Jhaveri	
16:20 - 16:40	Neoadjuvant response of rectal cancer: Guidelines for imaging and reporting – S. Nougaret	
16:40 - 16:50	Scientific Presentation	
16:50 – 17:10	:10 Guidelines/recommendations for initial staging and follow-up of colon cancer – K.Krajewski	
17:10 - 17:30	0 GIST, NET, Leiomyoma, when to think about – M. D'Onofrio	
16:00 - 17:40	O Lymphoma/Myeloma: Also everyone concerned Stevenson	
16:00 – 16:20	Deauville criteria/ Ann Arbor/ Cheson/ Lugano staging and response assessment – S. Mulé	
16:20 - 16:40	Novel PET Tracers / Imaging technique for lymphomas – M. Mayerhoefer	
16:40 - 16:50	Scientific Presentation	
16:50 - 17:10	WB-MRI in myeloma and strategies to support clinical adoption – C. Messiou	
17:10 - 17:30	Prognostic and predictive value of molecular imaging in haematological malignancies – W. Oyen	
16:00 – 17:00	Hands-On Workshop 4 – Neuroendocrine Tumours	

Scientific Programme: Tuesday 26 September

○ TIME	♠ SUBJECT & SPEAKER	VENUE
08:00 - 09:00	Registration	
08:30 - 09:00	Breakfast Symposium	
09:00 - 10:40	Liver HCC/ICC: A heterogeneous disease	BP LT
09:00 - 09:20	HCC diagnostic criteria: west vs east – B. Taouli	
09:20 - 09:40	Not HCC but HCCs – M. Ronot	
09:40 - 09:50	Scientific Presentation	
09:50 - 10:10	Which GBCA in liver diagnosis imaging? What are the recommendations? – S. Mulé	
10:10 - 10:30	Intrahepatic cholangiocarcinoma: initial diagnosis and stagin	ng – B. Taouli
10:30 - 10:40	Questions & Discussion	
10:40 - 11:00	Break	
11:00 – 12:40	The near future part 1: Theranostic & new molecular probes	BP LT
11:00 - 11:20	Extended field of view PET/CT – R. Hicks	
11:20 - 11:40	FAP theranostics: ready for prime time? – K. Herrmann	
11:40 - 11:50	Scientific Presentation	
11:50 - 12:10	PSMA theranostics: a new standard-of-care but what's next? – M. Hofman	
12:10 - 12:30	Radiogenomics: The emerging and future impact on treatment selection and monitoring in prostate cancer focal therapy – F. Fennessy	
12:30 - 12:40	Questions & Discussion	
11:00 - 12:40	Interventional Radiology, so helpful!	Stevenson
11:00 - 11:20	Guidelines for treatment of HCC and upcoming improvement radiology – R. lezzi	it in interventional
11:20 - 11:40	Percutaneous ablation of renal cancer: when and how? – J. Fi	ütterer
11:40 - 11:50	Scientific Presentation	
11:50 - 12:10	Biopsy in the chest: when and how? – S. Diederich	
12:10 - 12:30	Percutaneous treatment of the pain in oncology – B. Gebaue	r
12:30 - 12:40	Questions & Discussion	
11:00 - 12:00	Hands-On Workshop 5 – MRI in rectum and anal cancer; staging and prediction of tumour response K. Jhaveri	Rooms A&B
12:00 – 13:00	Hands-On Workshop 6 – Pancreas cancer work-up M. Wagner/ M. Zins	Rooms A&B
12:40 - 13:30	Lunch & 30-minute Satellite Symposium	

○ TIME	♠ SUBJECT & SPEAKER	VENUE
13:30 - 14:00	Keynote Lecture 2: CEST imaging – Professor Sotirios Bisdas	BP LT
14:00 - 15:30	My most impressive and astonishing cases, the ones I want to show to everyone!	BP LT
14:00 - 14:15	Gold Medal presentation	
14:15 - 14:25	Scientific Presentation	
14:30 - 14:40		A. Vargas
14:40 - 14:50		S. Voss
14:50 - 15:00		B. Taouli
15:00 - 15:10		G. Morana (Treviso)
15:10 - 15:20		E. Sala
15:20 - 15:30		P. Khong
15:30 - 16:00	Break	
16:00 - 17:40	The female cancers	BP LT
16:00 - 16:20	O-RADS US and MRI – A. Rockall	
16:20 - 16:40	MRI of the breast: when? – S. Vinnicombe	
16:40 - 16:50	Scientific Presentation	
16:50 – 17:10	Staging of cervical cancer: which imaging for which inform and more) – R. Forstner	nation? (FIGO staging
17:10 - 17:30	Guidelines for initial imaging of endometrium cancer – F. Fennessy	
17:30 - 17:40	Questions & Discussion	
16:00 - 17:40	Paediatrics: not to be neglected	Stevenson
16:00 - 16:20	COG/SPR whitepapers – A. Towbin	
16:20 - 16:40	INSTRuCT (International Soft Tissue sarcoma ConsorTium) Imaging Guidelines for Rhabdomyosarcoma – B. McCarville	
16:40 - 16:50	Scientific Presentation	
16:50 – 17:10	Functional imaging recommendations for bone and soft tissue sarcomas – S. Voss	
17:10 - 17:30	A "better" understanding of embryonal CNS tumours in children – T. Huisman	
17:30 - 17:40	Questions & Discussion	
16:00 – 17:00	Hands-On Workshop 7 – LI-RADS W. Schima / J. Heiken	Rooms A&B
19:30	Course Dinner in the Nereid Gallery, British Museum	

Scientific Programme: Wednesday 27 September

TIME	♠ SUBJECT & SPEAKER	VENUE
08:00 - 08:30	Breakfast Symposium	
08:30 - 10:00	Along the Urinary tract : Kidney/Bladder/Prostate BP LT	
08:30 - 08:46	Guidelines for prostate initial diagnosis and active surveillance (EAU clinical guidelines, PI-RADS and more) – R. Renard Penna	
08:46 - 09:02	How introduction of PSMA PET/CT completely changed prostate cancer staging – W. Oyen	
09:02 - 09:18	How to explore renal masses: guidelines or recommendations –	A.Shinagare
09:18 - 09:34	Testicular tumour: which imaging technique for which diagnosis	? – A. Sohaib
09:34 - 09:50	MRI pathway for bladder cancer and VI-RADS score: where we are and what's next – V. Panebianco	
09:50 - 10:00	Questions & Discussion	
08:30 - 10:30	The near future part 2: what we are going to use?	Stevenson
08:30 - 08:50	Imaging of the tumour microenvironment – A.Van den Abbeele	
08:50 - 09:10	Current guidelines for cancer screening with WB-MRI in high-risk populations – G. Petralia	
09:10 - 09:30	Al/Radiomics 2.0: How to increase translation to the clinical environment? – N. Papanikolaou	
09:30 - 09:50	Recommendations for the use of radiomics and machine learning – F. Prior	
09:50 - 10:00	Questions & Discussion	
10:00 - 10:30	- 10:30 Break	
10:30 - 12:00	MSK & Sarcoma: Not to be forgotten	BP LT
10:30 - 10:50	50 Imaging of bone metastases – G. Petralia	
10:50 - 11:10	MET-RADS case illustrations (Response assessments of metastatic bone disease) – A. Padhani	
11:10 - 11:30	Is this a lipoma or not? – C. Messiou	
11:30 - 11:50	Is this a leiomyosarcoma or not? – F. Fennessy	
11:50 - 12:00	Questions & Discussion	
10:30 – 11:30	Hands-On Workshop 8 – O-RADS G. Lin	Rooms A&E

○ TIME	TIME SUBJECT & SPEAKER	
12:00 - 13:15	Imaging of Chemotherapy/ Immunotherapy related injuries: To always keep in mind	BP LT
12:00 - 12:20	Thoracic toxicities - N. Sverzellati	
12:20 - 12:40	Abdominal toxicities – T. Persigehl	
12:40 - 13:00	Neurological toxicities – G. Morana (Turin)	
13:00 - 13:10	Questions & Discussion	
13:10 - 13:15	Closing remarks P. Khong	
13:15 - 14:00	Lunch	

Future ICIS Interactive Hands-on Workshops

Thursday 9 & Friday 10 November 2023
ICISi Masterclass in Head & Neck Cancer Imaging

New online course (delivered over two half-days)

Tuesday 12 December 2023

ICISi Masterclass in Oncological Whole-Body MRI, 2nd Edition

Online course

Wednesday 24 & Thursday 25 January 2024
ICISi Masterclass in Current Topics in Renal and Adrenal
Imaging

New online course (delivered over two half-days)

Scientific Papers

Monday 25 September

SCIENTIFIC SESSION 1

09.40 - 09.50

BP

Yin-Tzu Lin

Performance of Deep Learning Model on Automated Lesion Detection: Virtual Monoenergetic Images on Dual-Energy CT

SCIENTIFIC SESSION 2

11.40 - 11.50

BP

Wolfgang Kunz

Patterns of Pseudoprogression Across Different Cancer Entities Treated with Immune Checkpoint Inhibitors

SCIENTIFIC SESSION 3

11.40 - 11.50

Stevenson

Peter Strouhal

Clinical Utility of Deep Learning Algorithm To Achieve Pin-sharp Images Quicker: Real World Experience Across Multiple Sites

SCIENTIFIC SESSION 4

14.40 – 14.50

BP

Peter Strouhal

Applications of Spectral CT Technology in Routine Out-patient/CDC Setting

SCIENTIFIC SESSION 5

16.40 – 16.50

BP

Usman Bashir

Feasibility of AI as a liver screening tool for staging CT scans of colorectal cancer patients

SCIENTIFIC SESSION 6

16.40 – 16.50

Stevenson

Wolfgang Kunz

Lugano Criteria Modification by Pre-Infusion Kinetics Improves Survival Prediction in Chimeric Antigen Receptor T-Cell Therapy for Lymphoma

Tuesday 26 September

SCIENTIFIC SESSION 7

9.40 - 09.50

BF

Polat Goktas

Advanced Cellular Characterization via Modified UNet Framework in High-Throughput Microscopy Imaging

SCIENTIFIC SESSION 8

11.40 - 11.50

BP

Yael Eshet

The Role of Ga-68 FAPI PET/CT in breast cancer treatment response assessment and follow-up

SCIENTIFIC SESSION 9

11.40 – 11.50

Stevenson

Ana Castro Verde

Radiologic-histopathologic registration for biological validation of prostate cancer radiomics signatures

SCIENTIFIC SESSION 10

14.40 – 14.50

BP

Giacomo Feliciani

Radiopsy: WBMRI-ADC Quantitative Features for Discrimination of Smoldering and Multiple Myeloma in a prospective study

SCIENTIFIC SESSION 11

16.40 – 16.50

BP

Elaine Lee

Treatment response evaluation by PET/CT and CT after neoadjuvant chemotherapy in advanced ovarian cancer

SCIENTIFIC SESSION 12

16.40 – 16.50

Stevenson

Shrujal Jain

Quantification of visceral and subcutaneous fat on CT as predictors of outcome in endometrial cancer

Posters

01	Intra-abdominal Hemorrhage from Spontaneous Rupture of Visceral Tumors: CT Findings	Fabio Sandomenico
02	CT assessment of advanced ovarian cancer: findings precluding primary cytoreductive surgery	Sarah Natas
03	Abdominal emergencies in oncologic patients: "Elementary, my dear Watson."	Olga Nikolaidou
04	Deep invasion volume of primary nasopharyngeal carcinoma is a strong predictor of outcome	Qiyong Ai
05	Dual energy CT applications in oncologic imaging	Nils Große Hokamp
06	Chemotherapy-Related Cognitive Impairment (CRCI) in Breast Cancer: an ALE Meta-Analysis of Neuroimaging Studies	Sonya Utecht
07	Influence of the "Streamline Phenomenon" on the Laterality of Hepatic Metastases from Colorectal Cancer	Eduardo Medeiros
80	F-18 FDG, F-18 PSMA, and Cu-64 DOTATATE PET/ CT: One Patient, Three Cancers	Josh Eichhorn
09	Al for prostate MRI: results from a large multi- centre, multi-vendor external validation study	Aarti Shah
10	Integrating clinical data with AI to optimise decision-making in prostate MRI	Antony Rix
11	Lung Carcinoma with Atrial Invasion	Jia Huey Wong
12	Radiomics for the differential diagnosis between ameloblastomas and odontogenic keratocysts on panoramic radiography	Kuo Feng Hung
13	The role of alternate diagnosing imaging in the era of LI-RADS for diagnosing Hepatocellular Carcinoma	Wan Hang Keith Chiu
14	18-F FDG PET/CT in the evaluation of Neurolymphomatosis	Alexander Crose
15	MRI Surveillance of Liver Metastasis in High Risk Uveal Melanoma	Chloe McMurray

Posters continued

16	Morphological and Functional Parameters of MRI in Pet/Ct Proven Local Pancreatic Cancer Recurrences	Dusan Saponjski
17	Colocolic intussusception caused by multiple grouped Vanek's tumors: A case report	Dusan Saponjski
18	Developing a day-case radiologically inserted gastrostomy (RIG) service	Neel Raja
19	Sorting the imaging: improved metadata indices of The Cancer Imaging Archive	Tracy Nolan
20	Boosting Cancer Therapy: A Supervised Clustering Based on Interpretable Machine Learning Optimize Mesenchymal Cell Separation	Polat Goktas
21	Reliability analysis of a previously proposed MRI radiomics model for the detection of nasopharyngeal carcinoma	Mlun Wong
22	Facing a Dilema: Leiomyosarcoma or Leiomyoma?	Silvina De Luca
23	MRI assessment for bladder cancer: Unveiling the VI-RADS classification	Silvina De Luca
24	Role of 18 FDG PET CT in esophageal cancer	Silvina De Luca
25	Reducing the carbon footprint of cancer imaging storage	YiFan Jia
26	Pseudocirrhosis post chemotherapy breast cancer metastatic liver, our experience	Silvina De Luca
27	Outcomes of Targeted Liver Biopsy in Patients Presenting Acutely with Metastatic Cancer	Siva Muthukumarasamy
28	Comparison of ADC and PSA density for risk stratification of MRI Likert 3 prostate lesions	Paul Burn
29	Review of Sentinel Node SPECTCT For Nodal Staging in Cutaneous Melanoma	Michael Kay
30	Radiology Pathway Navigation – A New Direction	Louisa Edwards-Brown



Oncology Solutions

Where cancer and care connect.

GE HealthCare unites cancer screening with precision image guided therapy through an ecosystem of digital solutions, powered by AI, to create seamless coordination and advance the patient journey throughout the entire pathway from early detection, to follow up and assessment.

Together, we pursue precise connected care for all.

gehealthcare.com



Exhibitors and Sponsors



ICIS

The International Cancer Imaging Society (ICIS) was established to meet the important challenges of advancing imaging in the multidisciplinary management of cancer. The Society is open to all with an interest in cancer imaging. We run an annual teaching course as well as hands-on computer workshops covering a wide range of topics – see p11 for our upcoming courses.

Join The International Cancer Imaging Society today! Benefits include discounted registration fees at our teaching courses and workshops, access to member-only parts of the ICIS website featuring lectures from past teaching courses, 20% discount on the article processing charge for Cancer Imaging, and complimentary bi-monthly webinars.

Please have a chat with a member of the ICIS team at the ICIS registration desk to hear more about ICIS and the benefits of membership.

icimagingsociety.org.uk

The ICIS 2024 Annual Teaching Course will be held in Singapore in September 2024, in collaboration with the Singapore Radiological Society and the Singapore College of Radiologists.

We hope you will join us at our first annual course to be held in Asia!



As the official journal of the International Cancer Imaging Society, and written by renowned international experts in the field, Cancer Imaging encompasses the interdisciplinary and innovative field of cancer imaging, publishing the latest original research, reviews, case series, and editorials. The journal's open access format provides a highly visible forum to radiologists, nuclear medicine specialists, oncologists, oncological surgeons, and those interested in the field. Submit your articles @ cancerimagingjournal.com

ICIS wishes to thank all the following companies who are supporting this 22nd Annual Teaching Course.

Please be sure to visit their representatives in the exhibition during ICIS 2023.



Bayer

With over 100 years of expertise in diagnostic imaging, Bayer's Radiology business is well placed to be the partner of choice in helping radiology services address the many challenges they face today. Bayer's technologically advanced injectors, MRI contrast media and supporting digital ecosystem of software and workflow solutions aim to help Radiology departments achieve consistent scan results, increased diagnostic confidence and operational efficiency for the benefit of patient care

radiology.bayer.co.uk



Bracco

The Bracco Group is a world-leading diagnostic imaging provider. It develops, manufactures, and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need.

braccoimaging.com



Deeplink Medical

Deeplink Medical revolutionizes the medicine of today by providing easy solutions based on the latest trends and in line with global best practices (ISO 27001, HDS).

Deeplink Medical has created the platform MIRIO for the imaging and data workflow of your Oncology trials combined with medical services.

Deeplink Medical's team is sensitive to cancer research, a leading cause of mortality in the world, and we always seek to improve the practices in the sector through our services.

deeplink-medical.com

Exhibitors and Sponsors continued



GE HealthCare

Where cancer and care connect.

GE HealthCare unites cancer screening with precision image guided therapy through eco-system of devices and digital solutions powered by AI to create seamless coordination and advance the patient journey throughout the entire pathway from early detection to follow up and assessment.

Our collaborations, solutions and expertise drive optimization and transform personalized cancer care for improved outcomes.

Together, we pursue precise connected care for all. gehealthcare.com

Guerbet | **!!!**

Guerbet

Guerbet is a French pharmaceutical group that has been supporting healthcare professionals specialized in Diagnostic and Interventional Medical Imaging since 1926. Guerbet develops and markets contrast media, delivery systems, medical devices and related solutions adapted to their needs.

The company was founded in 1926 by André Guerbet. Since then, it has expanded significantly, thanks to the discovery of innovations that have left their mark on medical imaging technologies and the contrast media associated with them. Guerbet now sells a comprehensive range of products suitable for X-Ray and Magnetic Resonance Imaging (MRI).

guerbet.com



Hermes Medical Solutions

Established in 1976 in Stockholm, Hermes Medical Solutions continues to innovate its Hermia molecular imaging software to enable faster and more personalized diagnosis and therapies, increasing the efficiency of your centre and improving the outcomes for your oncology patients.

Hermia is designed to give you all the molecular imaging tools you need to support your diagnostic and therapeutic oncology workload, including reporting and analysis and practical, regulatory-approved personalized dosimetry workflows for internal radionuclide therapy in ONE powerful, vendor-neutral platform.

hermesmedical.com

Exhibitors and Sponsors continued



Mint Medical GmbH

Mint Medical is a German MedTech company with a subsidiary in Hamilton, NJ, USA. The company specializes in standardized computer-assisted evaluation and analysis of imaging and clinical data. Its software platform mint Lesion™ supports structured oncological radiological evaluation according to defined criteria and workflows in clinical trials and clinical routine, and is used worldwide in university hospitals, cancer centers and practices. Leading CROs and pharmaceutical companies use it to evaluate the efficacy of novel treatments in cancer and other diseases.

mint-medical.com



Olea Medical

Olea Medical offers a powerful multi-vendor and multi-modality oncology solution that can receive images from different PACS or modalities, and that tremendously improves the patient care workflow. Reliable Al-driven tools include comprehensive solutions for both CT and MRI.

olea-medical.com



Seimens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with Al-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide highquality, efficient care to patients.

In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 65,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

Exhibitors and Sponsors *continued*

Siemens Healthineers' PETNET Solutions, a global PET radiopharmaceutical network, leads the way in industry expertise. Providing routine, reliable delivery of high-quality radiopharmaceuticals and services has established PETNET Solutions as the trusted partner in PET imaging since 1996.

siemens-healthineers.com



ICIS 2023 Social Events & Sponsor Lectures

ICIS 2023 Course Dinner

- Tuesday 26 September, 19:30
- Nereid Gallery, British Museum

Join us for this unique opportunity to dine amongst the Gods and Goddesses of ancient civilisations!

Purchase your ticket from the ICIS registration desk by the end of lectures on Monday 25 September – we often sell out so make sure you don't miss out!

Each ticket costs £95 and includes a three course dinner with drinks, followed by tea/coffee. During the dinner we will award prizes for the best posters and oral presentations. We hope to see you there!

Lunch symposium – hosted by Siemens Healthineers

- Monday 25 September 13.00
- Stevenson

Presentation:

Abbreviated liver MRI for HCC surveillance

Speaker:

Dr Bachir Taouli, Professor of Radiology & Medicine, at Mount Sinai Hospital, New York.

Abbreviated MRI approach became a hot topic in liver imaging recently challenging current clinical practice guidelines which could contribute to delayed diagnosis and increased mortality in some cases. Abbreviated MRI protocols tailored for early-stage detection of HCC, has been proposed as an alternative surveillance option that provides high sensitivity and specificity. Join us to learn the latest advancements in abbreviated liver MRI.

Lunch symposium – hosted by Guerbet

- Tuesday 26 September 13.00
- Stevenson

Presentation:

Oncological imaging: How to improve detection with AI

Speakers:

Dr. Marc Zins (Paris Saint-Joseph Hospital Group, France), Dr. Riccardo Sartoris (Beaujon Hospital, AP-HP, France) & Rebeca Vetil (LTCI, Télécom Paris, Al medical imaging scientist, Guerbet) will discuss the promising results of a deep learning-based detection algorithm for focal liver lesions in patients with colorectal adenocarcinoma, and review performance of a new Al algorithm developed for the challenge of detecting early signs of pancreatic cancer.

Breakfast symposium – hosted by GE HealthCare

- Wednesday 27 September 08.00
- Stevenson

Presentation:

Tools, technologies and opportunities that can empower diagnostic shifts in staging cancer care

Speakers:

Dr Mathias Goyen, Chief Medical Officer, GE HealthCare EMEA

Join Prof. Dr. med. Mathias Goyen and the GE HealthCare team to learn more about advances and emerging opportunities in cancer staging. Dr. Goyen is currently the Chief Medical Officer EMEA for GE HealthCare and responsible for the medical, clinical and evidence generation strategies for product modalities in Europe, the Middle East and Africa.

Newsletter

Subscribe to our eNewsletter

Keep up to date with updates about our free webinars, online and classroom courses and Cancer Imaging Journal latest articles.

Sign up here





Instagram

ICIS have joined Instagram! Follow the International Cancer Imaging Society to keep up to date with all our latest free webinars, courses, interesting case discussions, and much more!



Submit your articles to our Society open access online journal - cancerimaging journal.com



Cancer Imaging

IMPACT FACTOR **NOW 4.9!**

5-YEAR IMPACT FACTOR **4.7** 14 DAYS
TO FIRST
DECISION
(Median)

798,074
DOWNLOADS
THROUGH
2022

Imaging in Comprehensive Cancer Care

Create a world without fear of cancer





Screening & Early Detection



Diagnosis & Therapy Decision



Treatment Planning & Delivery



Follow-up & Survivorship

Addressing the entire cancer care pathway

Our solutions span the entire Cancer Care Continuum, from screening and early detection, through diagnosis, therapy and survivorship. In addition to driving speed and precision, these solutions seek to streamline workflows and empower cancer care teams to improve performance and meet unique and evolving patient needs.



Visit us at siemens-healthineers.com/ clinical-specialities/oncology





ICIS Annual Teaching Course 2024 – Joint meeting with SGCR-WIRES

Cancer Imaging: Illuminating Cancer Care
The evolving role of imaging and intervention in the
patient journey

27-29 September 2024 Singapore







Call for Abstracts Deadline: to be announced

President: Professor Pek-Lan Khong

For full details & further information: icimagingsociety.org.uk | admin@cancerimagingsociety.org.uk